Search details
1.
Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study.
J Med Virol
; 90(11): 1739-1744, 2018 11.
Article
in English
| MEDLINE | ID: mdl-29900553
2.
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
J Hepatol
; 67(4): 700-707, 2017 10.
Article
in English
| MEDLINE | ID: mdl-28645740
3.
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Lancet
; 385(9986): 2502-9, 2015 Jun 20.
Article
in English
| MEDLINE | ID: mdl-25837829
4.
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Gastroenterology
; 149(4): 971-80.e1, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-26170136
5.
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
J Gastroenterol Hepatol
; 31(10): 1674-1683, 2016 Oct.
Article
in English
| MEDLINE | ID: mdl-26936417
6.
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Gastroenterology
; 147(2): 366-76.e6, 2014 Aug.
Article
in English
| MEDLINE | ID: mdl-24727022
7.
Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.
Clin Infect Dis
; 59(12): 1657-65, 2014 Dec 15.
Article
in English
| MEDLINE | ID: mdl-25266289
8.
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.
Clin Gastroenterol Hepatol
; 12(6): 1029-37.e5, 2014 Jun.
Article
in English
| MEDLINE | ID: mdl-24120953
9.
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.
J Hepatol
; 59(1): 11-7, 2013 Jul.
Article
in English
| MEDLINE | ID: mdl-23439259
10.
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
Lancet Gastroenterol Hepatol
; 5(9): 839-849, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32682494
11.
Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.
Eur J Drug Metab Pharmacokinet
; 44(1): 43-52, 2019 Feb.
Article
in English
| MEDLINE | ID: mdl-29909549
12.
Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II).
Health Sci Rep
; 2(3): e92, 2019 Mar.
Article
in English
| MEDLINE | ID: mdl-30937389
13.
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.
Open Forum Infect Dis
; 4(3): ofx154, 2017.
Article
in English
| MEDLINE | ID: mdl-28948180
14.
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study.
J Gastroenterol
; 51(4): 390-403, 2016 Apr.
Article
in English
| MEDLINE | ID: mdl-26403160
15.
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
Lancet Gastroenterol Hepatol
; 1(1): 25-35, 2016 09.
Article
in English
| MEDLINE | ID: mdl-28404108
16.
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Lancet Gastroenterol Hepatol
; 1(1): 36-44, 2016 09.
Article
in English
| MEDLINE | ID: mdl-28404110
17.
Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study.
J Gastroenterol
; 50(2): 238-48, 2015 Feb.
Article
in English
| MEDLINE | ID: mdl-25115901
18.
Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.
Virology
; 443(2): 278-84, 2013 Sep 01.
Article
in English
| MEDLINE | ID: mdl-23763767
19.
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
Antiviral Res
; 99(3): 214-20, 2013 Sep.
Article
in English
| MEDLINE | ID: mdl-23747481
20.
Efficacy and safety of paritaprevir/ritonavir/ombitasvir combined with dasabuvir in non-cirrhotic Asian adult patients with newly diagnosed and treated chronic HCV genotype 1b infection: a randomized, double-blind, placebo-controlled study - China data / 中华肝脏病杂志
Chinese Journal of Hepatology
; (12): 359-364, 2018.
Article
in Zh
| WPRIM | ID: wpr-806560